BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29463149)

  • 21. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
    Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
    J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities.
    Fornari D; Rebolj M; Bjerregård B; Lidang M; Christensen I; Høgdall E; Bonde J
    Cytopathology; 2016 Aug; 27(4):249-60. PubMed ID: 26990233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.
    Lee DH; Hwang NR; Lim MC; Yoo CW; Joo J; Kim JY; Park SY; Hwang SH
    Ann Clin Biochem; 2016 Sep; 53(Pt 5):561-7. PubMed ID: 26486441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
    Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
    BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
    Cuschieri K; Cubie H; Graham C; Rowan J; Hardie A; Horne A; Earle CB; Bailey A; Crosbie EJ; Kitchener H
    J Clin Virol; 2014 Feb; 59(2):104-8. PubMed ID: 24380720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
    Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
    J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV testing by cobas HPV test in a population from Catalonia.
    Lloveras B; Gomez S; Alameda F; Bellosillo B; Mojal S; Muset M; Parra M; Palomares JC; Serrano S
    PLoS One; 2013; 8(3):e58153. PubMed ID: 23483984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
    Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
    Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
    Castle PE; Eaton B; Reid J; Getman D; Dockter J
    J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test.
    Bernal S; Palomares JC; Artura A; Parra M; Cabezas JL; Robles A; Martín Mazuelos E
    J Clin Virol; 2014 Dec; 61(4):548-52. PubMed ID: 25453566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings.
    Xue P; Gao LL; Yin J; Han LL; Zhao J; Li L; Seery S; Han XY; Li TY; Jiang Y; Chen W; Shen J
    J Med Virol; 2019 Jul; 91(7):1342-1350. PubMed ID: 30854653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.
    Moore C; Duvall E; Braby E; Reid G; Docherty E; Grieve L; Cubie H; Graham C; Cuschieri K
    J Clin Virol; 2016 Jun; 79():32-35. PubMed ID: 27060653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the f-HPV typing™ and Hybrid Capture II® assays for detection of high-risk HPV genotypes in cervical samples.
    Cañadas MP; Cirigliano V; Darwich L; Sirera G; Coll J; Clotet B; Videla S
    J Virol Methods; 2012 Jul; 183(1):14-8. PubMed ID: 22449759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.
    Bottari F; Sideri M; Gulmini C; Igidbashian S; Tricca A; Casadio C; Carinelli S; Boveri S; Ejegod D; Bonde J; Sandri MT
    J Clin Microbiol; 2015 Jul; 53(7):2109-14. PubMed ID: 25903574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EUROarray human papillomavirus (HPV) assay is highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
    Cornall AM; Poljak M; Garland SM; Phillips S; Machalek DA; Tan JH; Quinn MA; Tabrizi SN
    Eur J Clin Microbiol Infect Dis; 2016 Jun; 35(6):1033-6. PubMed ID: 27048314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
    Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
    J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
    J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.
    Anand KV; Pimple SA; Bhattacharjee A; Mishra GA; Shastri SS
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2709-2716. PubMed ID: 34452578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.
    Jones J; Powell NG; Tristram A; Fiander AN; Hibbitts S
    J Clin Virol; 2009 Jun; 45(2):100-4. PubMed ID: 19394266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.